U.S. Clinical Sites for Phase 1/2 Trial of RP1 in Patients with Solid Tumors on Track to Initiate by End of Year Additional Product Candidates RP2 and RP3 Continue to Advance Toward the Clinic WOBURN, Mass. , Nov. 14, 2018 (GLOBE NEWSWIRE) — Replimune Group Inc.